SubscribeProsonix Ltd, (Oxford, UK) and CBC Co. Ltd (Tokyo, Japan, hereinafter CBC), announce the renewal of an agreement to cover the commercialisation of Prosonix patented sonoprocessing technology.
The technology will be marketed exclusively by CBC in Japan under the Prosonix brand.
The deal comes follows on from Prosonix's acquisition of the C3 Technology business of Accentus plc on March 31st 2006. CBC had previously undertaken the marketing of the Accentus C3 Technology brand in Japan from 2003.
Prosonix vision is to become acknowledged world leaders in the commercialization of proprietary added value ultrasonic process solutions, and firmly intends to build upon the rapid growth and highly successful business development previously concluded under the C3 Technology brand.
CBC are a leading independent company in the marketing of technology differentiated products and services to the Japanese chemical and life sciences industries. CBC are the partner of choice for several global chemical businesses and have a number of strategic investments and JV's in a range of Far East chemical manufacturing companies. CBC have also been successful in securing high profile technology licenses and developing significant brand equity in Japan on behalf of their corporate partners. In the year ending March 2006 CBC achieved sales of approximately $500 million USD in life sciences.
Prosonix are based in new state-of-the-art facilities at the Oxford Science Park, Oxford UK. Prosonix teams of chemists and engineers work together to deliver a unique multidisciplinary approach to solving customers complex problems, leveraging proprietary intellectual property and patented bespoke sonoprocessing equipment for cost effective mutual advantage at commercial scale.
Prosonix technology can be applied at any stage during product development and is already proven across scale in a wide range of challenging industrial environments, and helps reducetime to market, enhance productivity, and improve product performance.
Core markets include Pharmaceuticals, and Minerals Processing, where Prosonix sonocrystallization technology is employed at commercial scale for the Complete Crystallization ControlTM of customer's products, processes and unit operations. Prosonix has rapidly evolving activities in the oil and gas markets, confectionary and bioprocessing.
Prosonix also have established a number of strategic partnerships with a range of global leading academic institutions and technology partners that places Prosonix firmly at the cutting edge of the next generation of commercial scale ultrasonic process intensification solutions.
These include international award winning CrystalGEM™ predictive crystallization technology, new SAX™ nanocrystallization technology, and a brand new area of focus in Sonobiocatalysis™.
Commenting the deal Prosonix CEO David Hipkiss, said:-
"I am absolutely delighted that we have been able to secure this agreement with CBC, which builds upon their previous 3 years focused business development efforts. Japan remains a key geographic market for Prosonix and with their extensive experience of marketing cutting edge technologies and validated track record,we believe CBC represent the ideal channel to market for Prosonix and this arrangement is fundamental to the success of our newly formed business. We look forward to launching our new company and brand with them to the Japanese market in 2006."
Adding his comments, Joe Akatsuka, Main Board Director of CBC said:-
"We are delighted to be working with Prosonix as their partner of choice for the commercialisation of their proprietary technology, and it complements our existing market focused, technology differentiated strategy perfectly. We see many excellent opportunities for the Prosonix technology across the Japanese Chemical and Life Science Industry and are anticipating considerable success."